Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials

摘要

Enzalutamide is an oral andro-gen receptor inhibitor thought to have several mechanisms of action, including disruption of nuclear translocation by the androgen receptor and DNA binding of hormone response elements.1 Abiraterone inhibits the enzymatic activity of P450cl7/ CYP17A1, a key regulator of steroid production. With their distinct mechanisms of action, these 2 therapies may also have different toxicity profiles.